Hims & Hers Health falls after law-firm notices ahead of class-action deadline

What happened

Hims & Hers Health (HIMS) fell 6.7% to $27.68 on October 30, 2026, after law-firm notices reminded investors of a November 2 deadline to seek lead plaintiff status or join a securities class action. The notices were reported by GlobeNewsWire and Newsfile Corp. The stock opened 3.9% below the previous close and traded 1.1 times its 20-day average on the session, a pattern consistent with investor reaction to company-specific legal developments.

How big was the move

The decline was 1.6 times a typical daily move for this stock and 4.4 percentage points worse than the healthcare sector median, which fell 2.3% on the day. The S&P 500 fell 1.8% on the day and fell 0.6% over five sessions, while Hims & Hers Health fell 0.1% over its last five sessions. With a beta of 2.49, the stock tends to move more than the market; this session’s drop was far larger than both the market and sector moves, reinforcing that the legal notices were the likely driver.

In the context of its recent history, the stock had 71 sessions with a decline of at least 6.7% in the past five years. Twenty trading days later the median result was a gain of 8.7%, and 40 of 71 were higher, suggesting sharp single-day losses have often been followed by recoveries, though outcomes vary widely.

The technical picture

The stock closed 4.3% below its 20-day moving average and 4.7% below its 50-day moving average, while remaining 2.4% above its 200-day moving average. The 50-day average is above the 200-day average, a sign of an established uptrend, and the stock had spent 31 consecutive trading days above the 200-day average. The 14-day Relative Strength Index was 45, in a neutral range between 30 and 70.

Over one month the shares fell 5.5%, over three months they fell 10.2%, and over one year they fell 40.6%, leaving the stock 42.7% below its 52-week high and 50.6 percentage points behind the S&P 500 for the one-year period. Volatility was 68% annualized over 60 days, lower than 71% of its own readings over five years, indicating recent price swings are high but not unprecedented for this stock.

Fundamentals and valuation

For the four quarters through June 30, 2026, revenue was $2.58 billion, which grew 28.0% from a year earlier. Diluted earnings per share were $-0.63, and earnings per share growth from a year earlier fell 178.3%. Gross margin was 64.7%, down from 76.2% a year earlier, while operating margin stood at 3.6%, compared with 6.2% a year earlier. Free-cash-flow margin was 3.5% and return on invested capital was 3.7%.

Share count over one year decreased by 9.7%, which partially offsets per-share weakness from operating performance. The stock’s free-cash-flow yield was 1.4%.

PromtFinance scores present a mixed picture. The company scored Positive on Value (72) and Quality (78). It scored Weak on Growth (39) and Momentum (32), and Very weak on Revisions (1) and Stability (17). Those readings highlight reasonable underlying margins and quality measures but weak near-term growth momentum and analyst sentiment.

Earnings and analyst expectations

Hims & Hers Health last reported on August 10, 2026, with earnings per share of $-0.37 against $-0.05 expected, 643.1% below estimates. The company has recorded zero consecutive quarters beating estimates and its average surprise over the last four reports was 100.0% below estimates. The typical two-day reaction after recent reports was that the stock rose 1.3%.

The next report is scheduled for November 9, 2026. Analysts provide a consensus price target of $32.17, 16.2% above the closing price, based on 20 analysts. Thirty-five percent of those analysts rate the stock Buy or Strong Buy, and the consensus rating is Hold, indicating a split view where some see upside but overall expectations remain cautious.

What to watch

• November 2, 2026: deadline to seek lead plaintiff status or join the securities class action, as noted in law-firm notices reported by GlobeNewsWire and Newsfile Corp.
• November 9, 2026: next earnings report date.
• Short-term technical levels: proximity to the 200-day average, currently 2.4% above its 200-day moving average, and the 50-day average which is above the 200-day average.
• Momentum and revisions indicators: PromtFinance Revisions score of 1 and Momentum score of 32 indicate watch for any changes in analyst guidance or revisions.